Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050842 · ClinicalTrials.gov registry record · Early Phase 1
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT01050842: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT01050842 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01050842, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Selective estrogen receptor modulators, such as raloxifene, may work together with bicalutamide to stop the growth of prostate cancer. PURPOSE: This clinical trial studies giving bicalutamide and raloxifene together in treating patients with metastatic or hormone-refractory prostate cancer.
Interventions
- DRUG raloxifene
- PROCEDURE quality-of-life assessment
- DRUG bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-10-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01050842
The ClinicalTrials.gov registry entry for NCT01050842 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which raloxifene is the first listed.
NCT01050842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01050842 about?
NCT01050842 is a clinical study titled "Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Selective estrogen receptor modulators, such as raloxifene, may work together with bicalutamide to stop the growth of prostate cancer. ...
What is the current status of trial NCT01050842?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2010-02. Estimated completion is 2012-10-04.
What interventions are being tested in trial NCT01050842?
The interventions under investigation include: raloxifene (DRUG), quality-of-life assessment (PROCEDURE), bicalutamide (DRUG).
Who is sponsoring clinical trial NCT01050842?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.